-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35

Benzinga·11/06/2026 17:45:37
Listen to the news
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.